AMICUS THERAPEUTICS INC (FOLD) Fundamental Analysis & Valuation

NASDAQ:FOLD • US03152W1099

Current stock price

14.375 USD
+0.01 (+0.03%)
Last:

This FOLD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. FOLD Profitability Analysis

1.1 Basic Checks

  • In the past year FOLD has reported negative net income.
  • In the past year FOLD had a positive cash flow from operations.
  • In the past 5 years FOLD always reported negative net income.
  • FOLD had negative operating cash flow in 4 of the past 5 years.
FOLD Yearly Net Income VS EBIT VS OCF VS FCFFOLD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100M -200M -300M

1.2 Ratios

  • With an excellent Return On Assets value of -2.85%, FOLD belongs to the best of the industry, outperforming 86.87% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -9.89%, FOLD belongs to the top of the industry, outperforming 86.49% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 3.83%, FOLD belongs to the top of the industry, outperforming 90.15% of the companies in the same industry.
Industry RankSector Rank
ROA -2.85%
ROE -9.89%
ROIC 3.83%
ROA(3y)-9.83%
ROA(5y)-17.97%
ROE(3y)-44.48%
ROE(5y)-81.46%
ROIC(3y)N/A
ROIC(5y)N/A
FOLD Yearly ROA, ROE, ROICFOLD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100 -150

1.3 Margins

  • FOLD has a better Operating Margin (5.44%) than 89.38% of its industry peers.
  • FOLD has a Gross Margin of 88.50%. This is amongst the best in the industry. FOLD outperforms 90.35% of its industry peers.
  • In the last couple of years the Gross Margin of FOLD has remained more or less at the same level.
Industry RankSector Rank
OM 5.44%
PM (TTM) N/A
GM 88.5%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.09%
GM growth 5Y0.1%
FOLD Yearly Profit, Operating, Gross MarginsFOLD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. FOLD Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so FOLD is destroying value.
  • The number of shares outstanding for FOLD has been increased compared to 1 year ago.
  • The number of shares outstanding for FOLD has been increased compared to 5 years ago.
  • The debt/assets ratio for FOLD has been reduced compared to a year ago.
FOLD Yearly Shares OutstandingFOLD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M
FOLD Yearly Total Debt VS Total AssetsFOLD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • Based on the Altman-Z score of 1.27, we must say that FOLD is in the distress zone and has some risk of bankruptcy.
  • FOLD has a Altman-Z score of 1.27. This is in the better half of the industry: FOLD outperforms 63.32% of its industry peers.
  • The Debt to FCF ratio of FOLD is 13.15, which is on the high side as it means it would take FOLD, 13.15 years of fcf income to pay off all of its debts.
  • FOLD has a better Debt to FCF ratio (13.15) than 90.54% of its industry peers.
  • A Debt/Equity ratio of 1.43 is on the high side and indicates that FOLD has dependencies on debt financing.
  • FOLD has a worse Debt to Equity ratio (1.43) than 77.99% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.43
Debt/FCF 13.15
Altman-Z 1.27
ROIC/WACC0.43
WACC8.84%
FOLD Yearly LT Debt VS Equity VS FCFFOLD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M

2.3 Liquidity

  • FOLD has a Current Ratio of 2.84. This indicates that FOLD is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of FOLD (2.84) is worse than 66.22% of its industry peers.
  • A Quick Ratio of 1.88 indicates that FOLD should not have too much problems paying its short term obligations.
  • With a Quick ratio value of 1.88, FOLD is not doing good in the industry: 76.64% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.84
Quick Ratio 1.88
FOLD Yearly Current Assets VS Current LiabilitesFOLD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. FOLD Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 58.33% over the past year.
  • The Revenue has grown by 20.05% in the past year. This is a very strong growth!
  • Measured over the past years, FOLD shows a quite strong growth in Revenue. The Revenue has been growing by 19.44% on average per year.
EPS 1Y (TTM)58.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-90%
Revenue 1Y (TTM)20.05%
Revenue growth 3Y24.43%
Revenue growth 5Y19.44%
Sales Q2Q%23.72%

3.2 Future

  • The Earnings Per Share is expected to grow by 107.92% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, FOLD will show a quite strong growth in Revenue. The Revenue will grow by 18.18% on average per year.
EPS Next Y534.7%
EPS Next 2Y230.38%
EPS Next 3Y175.47%
EPS Next 5Y107.92%
Revenue Next Year18.91%
Revenue Next 2Y18.63%
Revenue Next 3Y19.2%
Revenue Next 5Y18.18%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
FOLD Yearly Revenue VS EstimatesFOLD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B
FOLD Yearly EPS VS EstimatesFOLD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 1 -1 2 3

More info and screens

Find the best growth stocksShow best growing peers

5

4. FOLD Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for FOLD. In the last year negative earnings were reported.
  • FOLD is valuated quite expensively with a Price/Forward Earnings ratio of 44.09.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of FOLD indicates a rather cheap valuation: FOLD is cheaper than 90.54% of the companies listed in the same industry.
  • When comparing the Price/Forward Earnings ratio of FOLD to the average of the S&P500 Index (23.80), we can say FOLD is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 44.09
FOLD Price Earnings VS Forward Price EarningsFOLD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100 -150

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of FOLD indicates a rather cheap valuation: FOLD is cheaper than 89.38% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, FOLD is valued cheaper than 90.93% of the companies in the same industry.
Industry RankSector Rank
P/FCF 151.18
EV/EBITDA 108
FOLD Per share dataFOLD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2

4.3 Compensation for Growth

  • FOLD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as FOLD's earnings are expected to grow with 175.47% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y230.38%
EPS Next 3Y175.47%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. FOLD Dividend Analysis

5.1 Amount

  • No dividends for FOLD!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

FOLD Fundamentals: All Metrics, Ratios and Statistics

AMICUS THERAPEUTICS INC

NASDAQ:FOLD (3/19/2026, 9:41:08 AM)

14.375

+0.01 (+0.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-20
Earnings (Next)04-29
Inst Owners101.15%
Inst Owner Change1.99%
Ins Owners0.55%
Ins Owner Change-8.02%
Market Cap4.51B
Revenue(TTM)634.21M
Net Income(TTM)-27.11M
Analysts71.43
Price Target15.81 (9.98%)
Short Float %6.25%
Short Ratio2.7
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-20.92%
Min EPS beat(2)-94.35%
Max EPS beat(2)52.51%
EPS beat(4)2
Avg EPS beat(4)-6.54%
Min EPS beat(4)-94.35%
Max EPS beat(4)52.51%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)0.26%
Min Revenue beat(2)0.02%
Max Revenue beat(2)0.49%
Revenue beat(4)3
Avg Revenue beat(4)-1.5%
Min Revenue beat(4)-9.62%
Max Revenue beat(4)3.12%
Revenue beat(8)5
Avg Revenue beat(8)-0.57%
Revenue beat(12)8
Avg Revenue beat(12)-0.07%
Revenue beat(16)10
Avg Revenue beat(16)-0.84%
PT rev (1m)0%
PT rev (3m)-5.8%
EPS NQ rev (1m)20.82%
EPS NQ rev (3m)27.46%
EPS NY rev (1m)0%
EPS NY rev (3m)19.01%
Revenue NQ rev (1m)0.26%
Revenue NQ rev (3m)-1.58%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.73%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 44.09
P/S 7.12
P/FCF 151.18
P/OCF 136.15
P/B 16.45
P/tB 72.17
EV/EBITDA 108
EPS(TTM)-0.08
EYN/A
EPS(NY)0.33
Fwd EY2.27%
FCF(TTM)0.1
FCFY0.66%
OCF(TTM)0.11
OCFY0.73%
SpS2.02
BVpS0.87
TBVpS0.2
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -2.85%
ROE -9.89%
ROCE 4.84%
ROIC 3.83%
ROICexc 6.51%
ROICexgc 13.18%
OM 5.44%
PM (TTM) N/A
GM 88.5%
FCFM 4.71%
ROA(3y)-9.83%
ROA(5y)-17.97%
ROE(3y)-44.48%
ROE(5y)-81.46%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.09%
GM growth 5Y0.1%
F-Score4
Asset Turnover0.67
Health
Industry RankSector Rank
Debt/Equity 1.43
Debt/FCF 13.15
Debt/EBITDA 9.36
Cap/Depr 44.18%
Cap/Sales 0.52%
Interest Coverage 0.79
Cash Conversion 79.01%
Profit Quality N/A
Current Ratio 2.84
Quick Ratio 1.88
Altman-Z 1.27
F-Score4
WACC8.84%
ROIC/WACC0.43
Cap/Depr(3y)60.08%
Cap/Depr(5y)62.67%
Cap/Sales(3y)1.02%
Cap/Sales(5y)1.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-90%
EPS Next Y534.7%
EPS Next 2Y230.38%
EPS Next 3Y175.47%
EPS Next 5Y107.92%
Revenue 1Y (TTM)20.05%
Revenue growth 3Y24.43%
Revenue growth 5Y19.44%
Sales Q2Q%23.72%
Revenue Next Year18.91%
Revenue Next 2Y18.63%
Revenue Next 3Y19.2%
Revenue Next 5Y18.18%
EBIT growth 1Y1.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year142.25%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y179.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y197.8%
OCF growth 3YN/A
OCF growth 5YN/A

AMICUS THERAPEUTICS INC / FOLD Fundamental Analysis FAQ

What is the fundamental rating for FOLD stock?

ChartMill assigns a fundamental rating of 4 / 10 to FOLD.


What is the valuation status for FOLD stock?

ChartMill assigns a valuation rating of 5 / 10 to AMICUS THERAPEUTICS INC (FOLD). This can be considered as Fairly Valued.


Can you provide the profitability details for AMICUS THERAPEUTICS INC?

AMICUS THERAPEUTICS INC (FOLD) has a profitability rating of 4 / 10.


What is the expected EPS growth for AMICUS THERAPEUTICS INC (FOLD) stock?

The Earnings per Share (EPS) of AMICUS THERAPEUTICS INC (FOLD) is expected to grow by 534.7% in the next year.